StockMarketWire.com - AstraZeneca and MedImmune said Friday a clinical trial evaluating the efficacy of its head and neck cancer treatment failed to meet its primary goal of improving death rates.

Imfinzi monotherapy and the combination of Imfinzi plus tremelimumab did not meet the primary endpoints of improving death rates compared to standard-of-care chemotherapy in patients who had received prior chemotherapy to treat head and neck cancer.

'The prognosis for recurrent or metastatic head and neck squamous cell cancer is very poor and new treatments for this group of cancers are urgently needed,' chief medical officer Sean Bohen said.

'While these results are disappointing, we remain committed to evaluating the potential of Imfinzi and other innovative medicines for patients with head and neck cancer,' he added.

'We look forward to seeing the results of the Phase III KESTREL trial of Imfinzi and tremelimumab in patients who have not received prior chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma in the first half of 2019.'

Story provided by StockMarketWire.com